Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study

INTRODUCTION: To assess the impact of certolizumab pegol (CZP) treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes and to determine the treatment response time point most predictive of long-term outcomes in Italian patients with rheumatoid arthritis (RA). METHODS: CZP-SP...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarzi-Puttini, Piercarlo, Filippucci, Emilio, Adami, Silvano, Meroni, Pier Luigi, Batticciotto, Alberto, Idolazzi, Luca, De Lucia, Orazio, Talavera, Pablo, Kumke, Thomas, Grassi, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096970/
https://www.ncbi.nlm.nih.gov/pubmed/30043210
http://dx.doi.org/10.1007/s12325-018-0751-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096970/
https://www.ncbi.nlm.nih.gov/pubmed/30043210
http://dx.doi.org/10.1007/s12325-018-0751-8

Ejemplares similares